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Abstract Recent data indicate that the incidence of end-
stage renal disease (ESRD) in pediatric patients (age 0–
19 years) has increased over the past two decades.
Similarly, the prevalence of ESRD has increased threefold
over the same period. Hemodialysis (HD) continues to be
the most frequently utilized modality for renal replacement
therapy in incident pediatric ESRD patients. The number of
children on HD exceeded the sum total of those on
peritoneal dialysis and those undergoing pre-emptive renal
transplantation. Choosing the best vascular access option
for pediatric HD patients remains challenging. Despite a
national initiative for fistula first in the adult hemodialysis
population, the pediatric nephrology community in the
United States of America utilizes central venous catheters
as the primary dialysis access for most patients. Vascular
access management requires proper advance planning to
assure that the best permanent access is placed, seamless
communication involving a multidisciplinary team of
nephrologists, nurses, surgeons, and interventional radiol-
ogists, and ongoing monitoring to ensure a long life of use.
It is imperative that practitioners have a long-term vision to
decrease morbidity in this unique patient population. This
article reviews the various types of pediatric vascular
accesses used worldwide and the benefits and disadvan-
tages of these various forms of access.
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Introduction
The 2006 report of the United States Renal Data Systems
(USRDS) indicated that the incidence of end-stage renal
disease (ESRD) in pediatric patients (age 0–19 years) had
increased from 8.6 cases per million population in 1980 to
14.1 cases per million population in 2004 [1]. Similarly, the
prevalence of ESRD had increased from 28.3 to 81.1 cases
per million population over the same period. Hemodialysis
(HD) was the most frequently utilized modality for renal
replacement therapy in the 1,346 incident pediatric ESRD
cases in 2004. The 51% of children on HD exceeded those
on peritoneal dialysis (33%) and those undergoing pre-
emptive renal transplantation (16%). With regard to
prevalence, 68% of the 7,218 children with ESRD had a
functioning renal transplant. Of the remaining children
(2,311 patients) being treated with dialysis, the majority
(59%) were treated with hemodialysis [1].
“The ideal vascular access delivers a flow rate adequate
for the dialysis prescription, has a long use-life, and has a
low rate of complications (e.g. infection, stenosis, throm-
bosis, aneurysm, and limb ischemia)” [2]. The arteriove-
nous fistula (AVF) best approximates this definition.
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USA is a central venous catheter (CVC) as opposed to an
AVF or arteriovenous graft (AVG). Despite the increasing
focus on the potential morbidity associated with CVCs,
their usage rate at hemodialysis initiation has increased in
recent years, with usage rates of 89% for children <13 years
of age and 64% in those 13–19 years of age [1]. Review of
the 2006 Annual report of the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS) reveals
that the majority of pediatric patients (78.9%) receiving
hemodialysis have a CVC as primary access, in comparison
with AVF (12.3%) and AVG (8.5%) [3]. Dialysis termina-
tion in HD patients is most often due to transplantation or
patient choice. Specifically, patients with CVCs were more
likely to terminate hemodialysis within the first 6 months of
dialysis initiation. This would suggest that practitioners are
more likely to initiate hemodialysis with a CVC in patients
anticipated to receive transplants within a short time.
Despite the anticipation of shortened time to transplanta-
tion, USRDS data show that, in pediatric patients, the time
to first transplantation is actually increasing [1]. From
1996–2000, 75% of children under 11 years of age, and
90.3% of those 11 years of age or older, received a
transplant within 5 years of initiation; between 2001 and
2005, the percents were 70 and 79, respectively. Owing to
the variability in access use and times to transplantation, the
decision of which vascular access type is to be used
becomes even more of a conundrum.
Thus, it can be expected that practitioners will need to
focus increasing efforts toward optimizing care of the
pediatric hemodialysis patient. This is based on the trends
of increasing incident and prevalent rates for children with
ESRD, accompanied by the fact that HD is the most
commonly used modality in incident patients and preva-
lent patients requiring dialysis. Clearly, choosing the best
vascular access option in the pediatric hemodialysis
population remains challenging. Despite a national initia-
tive for fistula first in the adult hemodialysis population, to
date the pediatric nephrology community in the USA
utilizes the CVC as the primary dialysis access in a
majority of patients. Although AVFs should be generally
preferred in most patients, CVC use may be appropriate
in certain settings, including those patients expected
to receive a renal transplant within a short time and
exceptionally small children (weight <10 kg). Other
factors to be considered include the rate of progression
of chronic kidney disease or the patient’s desire to transfer
to peritoneal dialysis. This article will attempt to review
the various types of pediatric vascular accesses used
around the world and the benefits and disadvantages of
the various forms of accesses. When appropriate, we
attempt to offer suggestions for optimizing each type of
vascular access.
Arteriovenous fistulae
Historically, the original form of arteriovenous access and
the precursor of the modern-day AVF was the “Scribner
shunt”. This device, described in 1960, was the original
vascular access used to provide long-term hemodialysis for
adults. This vascular access consisted of two cannulae: one
inserted into the radial artery and the other into the adjacent
cephalic vein [4]. Considered to be dependable and reliable,
this shunt was still fraught with problems, as 50% were
reported to need at least one revision and 31% required
multiple revisions [5]. Additionally, the Scribner shunt had
an average life span of 113 days, with 40% requiring
removal for infection or clotting [6]. Nonetheless, the
reliability of this technique, and its subsequent modification
for use in children, provided the first form of long-term
vascular access for hemodialysis [7].
The first AVF was described by Brescia et al. in 1966
and subsequently has become the ideal vascular access in
both adults and children. This is mostly due to its low
complication rates and long life span [8, 9]. When AVF was
first attempted in children, a 50% immediate failure rate
was reported [10]. However, as few as 3 years later, Broyer
et al. reported acceptable results in 54% of distal AVFs in
children less than 20 kg in weight [11]. Over the years,
advances in AVF creation, especially with increased
surgical experience, have shown primary failure rates as
low as 5%. The preferred sites for AVF placement include,
in order, radial artery to cephalic vein (radiocephalic),
brachial artery to cephalic vein (brachiocephalic), and
brachial artery to basilic vein (brachiobasilic, with or
without transposition) [2]. Alternatively, an ulnar artery to
basilic vein AVF can be created. A femoral artery to
saphenous vein AVF has been described but is rarely used
[12]. Although preference is given to the non-dominant
forearm, ultimately, vessel size is the most important factor
in site selection. If the site with the largest possible venous
diameter is chosen, there is greater likelihood of successful
use of the AVF. Although definite guidelines regarding
minimum vessel size do not exist, general consensus
implies a preferred minimum of 2.5 mm venous diameter
[13]. Duplex ultrasound scanning by the surgeon, or
venography, can provide information regarding adequate
vessel size, venous stenosis, or occlusion, and should be
considered in pediatric patients so that the best location for
AVF placement can be determined [13].
The Centers for Medicare and Medicaid Services (CMS)
introduced the “Fistula First” initiative in 2003, with the
goal of achieving the guidelines of the National Kidney
Foundation/ Kidney Disease Outcomes and Quality Initia-
tive (NKF/K-DOQI). These guidelines recommend a 50%
AVF rate in all incident HD patients and a 40% prevalent
AVF rate in adult hemodialysis patients. This has not been
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goal is to provide HD with the best possible access, an
AVF needs to be considered in all pediatric HD popula-
t i o n sa sw e l l .I th a sb e e nt h ea u t h o r s ’ experience that high
AVF usage rates can be established through a multidisci-
plinary team approach involving pediatric nephrologists,
experienced HD nurses, vascular surgeons, interventional
radiologists and recreational therapists/child life special-
ists. Gradman et al. reported the successful creation of 47
AVFs in the USA by utilization of an operating micro-
scope in individuals with small arteries [13]. In fact, a
pediatric dialysis unit in Northern Ohio has an average
AVF usage rate of >80%. Microsurgical techniques have
been successfully utilized by an experienced vascular
surgeon to create AVFs in three children under 15 kg in
weight (Chand, unpublished data). Numerous reports of
successful creation of AVFs in children have been reported
throughout the world, with primary failure rates as low as
5% [14–16]. Time to maturation may be prolonged, with
reports of up to 6 months. Thus, early planning should be
undertaken to allow time for maturation and/or revision if
necessary.
Potential benefits of AVF creation include lower infec-
tion rate, lower thrombosis and stenosis rate, and greater
freedom with regards to activity. Infection rates for AVFs
and AVGs are approximately seven-times lower than those
for CVCs. After 6 months of receiving hemodialysis, only
5% of pediatric patients dialyzed via AVFs had developed
an access infection, in comparison with 36% of those
dialyzed via CVCs [1]. Children with an internal HD access
(AVF or AVG) enjoy the luxury of bathing and swimming
without concerns of infection risks. Possible complications
of AVFs include stenosis, thrombosis, possible leg length
discrepancy if the AVF is placed in the lower extremity, and
steal syndrome. Steal syndrome occurs when cardiac output
is diverted from the capillary bed by the AVF, causing distal
ischemia. Additionally, congestive heart failure has been
rarely associated with large AVFs in adults, particularly in
upper arm fistulae [17].
Arteriovenous grafts
Arteriovenous grafts (AVG) should be considered as an
option for hemodialysis access in children, especially in
those who require the replacement of native vessels to
perform an adequate anastomosis. Advantages and dis-
advantages of AVG in comparison with AVF are depicted in
Table 1. Alternative materials available include saphenous
vein, bovine, umbilical, Dacron, polyurethane, cryopre-
served femoral vein, and polytetrafluoroethylene (PTFE).
The PTFE graft is the most commonly utilized, due to the
fewest complication rates. One study comparing bovine
grafts with PTFE grafts demonstrated fewer complications
with PTFE ones, specifically fewer thromboses and lower
infection rates. Furthermore, the life span of the PTFE graft
is comparable to that of its predecessors; the PTFE graft is
easier to obtain and easier to repair [18]. Grafts are most
commonly placed in the forearm, between the brachial
artery and basilic or brachial vein [19]. Alternatively, grafts
can be placed between the brachial artery and basilic or
axillary vein, just below the axilla. The thigh, with the
femoral artery and femoral or saphenous vein being used, is
an alternative site often used in small children. Some
authors have reported the use of alternative, more creative,
AVGs in children in order to optimize care for the long
term. Lau et al. reported the combined use of polyurethane
and PTFE to create a composite AVG in a child who did not
have adequate vessels for an AVF [20]. This AVG was
successfully used until the time of transplantation. Of note,
higher infection rates have been noted with thigh grafts than
with upper extremity grafts [21, 22].
Advantages for the use of an AVG include a shorter time
to first use, higher primary patency rate, and ease of
technical creation. Sheth et al. reported the creation of 24
AVFs and 28 AVGs in 19 and 23 pediatric HD patients,
respectively. The primary failure rates were 33.3% and
3.6% in AVF and AVG, respectively. The most common
site of AVG placement was the thigh, in approximately
50% of patients. Access stenoses and infection were
reportedly higher in AVGs than in AVFs, but thrombotic
episodes were not significantly different [23]. Chand et al.
evaluated dialysis adequacy (Kt/V, urea reduction rates),
anemia management, and albumin status based on vascular
access type and found no significant differences between
AVFs and AVGs [24].
Disadvantages of AVG use include thrombosis, stenosis,
and infection. Ramage et al. reported long-term complica-
tion rates of AVFs compared with AVG in a retrospective
study conducted over a 20-year period. Intervention rates
were reported as 17.8% for AVFs and 33% for AVGs.
Reasons for discontinuation of AVG use was infection
(20%), thrombosis (73%), and planned termination of use
(6.7%) [9]. Furthermore, infections are problematic with
Table 1 Permanent vascular access options: AV fistula versus AV
graft
AV fistula AV graft
Lower infection rate Higher infection rate
Lower thrombosis rate Higher thrombosis rate
May take 3–6 months to mature Usually able to be used within
a few weeks
Primary failure rate is higher Primary failure rate is lower
Secondary failure rates lower Secondary failure rates higher
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occurrence is within weeks of placement or results in
sepsis. Steal syndrome, as described previously, is a
possible complication of AVGs, as well.
Central venous catheters
Central venous catheters are the most commonly used
vascular access in children in North America. A CVC is the
first choice of vascular access in the patient who requires
urgent hemodialysis, such as the patient who presents in
stage V chronic kidney disease (CKD). Alternatively, it can
serve as a bridge for a patient who is expected to receive a
planned renal transplant or is training to transfer to
peritoneal dialysis. There are advantages to a CVC,
including the ability for it to be used it immediately and
the absence of needle cannulation. However, the disadvan-
tages of using a CVC include its short life span, thrombosis,
infection, malfunction and possible fibrin sheath formation
[9]. The advantages and disadvantages of CVCs are
summarized in Table 2. Median survival times of CVCs
have been reported to range from 4 months to 10.6 months
[9, 25]. Goldstein et al. evaluated catheter survival times in
56 uncuffed and 22 cuffed CVCs. The median survival
period of the uncuffed catheters was only 31 days and of
cuffed catheters was 123 days. The 1-year survival rate of
long-term use of cuffed catheters was 27% [26]. In many
situations, CVC use cannot be avoided and may even be
warranted. In those children whose vasculature is too small
(particularly children weighing under 10 kg), especially
without an experienced surgeon, a CVC may be the best
temporary solution. However, periodic reassessments of the
vasculature also need to be made. Similarly, if a child has
extremity contractures, bony deformities, or other mobility
limiting conditions, a CVC may be the best choice to allow
nursing personnel ready access.
If a CVC is deemed to be the best option for a patient,
good communication between the nephrologist and sur-
geon/interventional radiologist regarding placement must
occur. First, the choice of location is paramount. The NKF/
K-DOQI guidelines recommend that the order of CVC
placement be sequential: the right internal jugular vein,
right external jugular vein, the left internal and external
jugular veins, subclavian veins, femoral veins, or trans-
lumbar access to the inferior vena cava [2]. This order is
based on complication rates from lowest to highest. For
example, Schon and Whittman found that the incidence of
stenosis was 27% for CVCs placed in the right internal
jugular vein in comparison with 40% for those placed in
the left internal jugular vein [27]. As such, there must be
discussion between the professional placing the CVC and
the nephrologist as to the optimal desired location. For
example, in order to achieve repeated consistently good
blood flow rates, the tip of the CVC should be placed in
the right atrium and the line needs to be long enough to be
in the appropriate location [28, 29]. When a child moves
vigorously, there is potential for the line to move as well.
The catheter tip can potentially move out of the right
atrium and provide inadequate dialysis. The largest
diameter CVC that can safely be placed should be chosen
to optimize blood flows as well. Furthermore, kinking of a
CVC can be a common problem. Goldstein et al. reported
kinking to be the most common reason for central line
removal in uncuffed catheters (36%) and second most
common reason in cuffed catheters (13.6%) [26]. Kinking
can potentially be prevented by bending the catheter in the
shape of a C or U prior to tunneling the line. This creates a
contiguous arc in the catheter to avoid constriction of the
lumen [27].
The most common reason for cuffed CVC removal is
infections. These can range from exit site infections to
tunnel infections to bacteremia. USRDS data have shown
sepsis rates associated with CVCs to approximate 80 per
100 patient-years, as compared to only 10 per 100 patient-
years for AVFs [1]. Potential consequences include septic
shock, subacute bacterial endocarditis, osteomyelitis and
epidural abscess [30, 31]. Infection risk can be decreased by
the use of sterile techniques when CVCs are being placed
or replaced, by hand washing between dialysis patients (not
just changing gloves), and by the use of antibacterial
antiseptic solutions for exit site care. One study evaluated
potential differences in infection rates based on the use of
three agents: 2% chlorhexidine, 10% povidone-iodine, and
70% alcohol, and found that the rates of infection in each
group were 0.5%, 2.6%, and 2.3%, respectively [32].
Table 2 Pros and cons of central venous catheters for hemodialysis in
children
Pros Cons
Easily placed Infection rates high
Can be used immediately Failure rates and replacement
rates high
Painless to the patient Blood flow rates are variable,
leading to potentially poor
clearance
Requires little planning prior
to placement
Permanent damage to central
venous system (stenosis/
thrombosis) may occur
Easily removed if used as
“transitional” access for future
PD or transplant patients
Damage to central vessels can
prohibit future AVF/AVG
placement in ipsilateral extremity
No vascular steal Possible Arrhythmia
Decreased risk of high-output
cardiac failure
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7.1%, respectively. When various occlusive dressings were
assessed, no difference in exit site infection rates was found
between transparent dressings and dressings with higher
transmissions of moisture vapor. Recently, antimicrobial
catheter locks (ACLs) have been used to reduce CVC
infection rates. Agents that have previously been used
include citrate, aminoglycosides, aminoglycosides + citrate,
aminoglycosides + heparin, minocycline + ethylenediamine
tetra-acetic acid (EDTA), cephalosporin-based solutions,
and vancomycin heparin locks. Gentamicin-based solutions
are the least expensive and are most likely the current
agents of choice. Concerns of antimicrobial resistance
preclude the use of vancomycin in most cases. Given that
minocycline is not commercially available, an alternative
would be doxycycline EDTA. Studies would suggest that
citrate is the ideal ACL solution; however, it is not available
in the USA [33].
Thrombus formation is another potential complication of
long-term CVC use. In a recent multi-center survey
conducted by Valentini et al., a clot was suspected by
dialysis providers in 26% of dysfunctional catheters [34]. It
can occur in the right atrial wall, on the vessel wall, or may
completely occlude the vessel. Tissue ingrowth into the
CVC itself has been reported and has entrapped the CVC
onto the endothelial surface of the vessel. This, potentially,
would require either leaving the CVC in the vessel
permanently or thoracotomy for removal [27, 35].
A common problem in long-term CVC use is the
formation of a fibrin sheath, which has been reported in
up to 50% of CVCs [35]. Over time, the sheath can
elongate, covering the intake and outflow holes of the
catheter, leading to dysfunction. Of note, if a CVC is
replaced into the same fibrin sheath, there will be no
improvement in flow, possibly making the vessel unusable.
Treatment options including infusion of thrombolytic
agents (i.e. tissue plasminogen activator or urokinase) and
fibrin sheath stripping, and disruption of the sheath at
catheter exchange has been reported, with varying success,
high costs, and potential complications [36–38].
For these reasons, the CVC remains a suboptimal choice
forhemodialysisvascularaccessandshouldbeconsideredas
a bridge to a more permanent, optimized, vascular access.
Caveats regarding placement of access
Early planning is critical in vascular access management.
To reiterate, the guidelines of The National Kidney
Foundation/ Kidney Disease Outcomes and Quality Initia-
tive (NKF/K-DOQI) recommend a 50% AVF rate in all
incident HD patients. Based on a recent study of 37
incident pediatric hemodialysis patients conducted in the
Midwestern USA, a majority of patients were followed-up
by a nephrologist for at least 6 months, however, a CVC
(83.7%) was the predominant vascular access at dialysis
initiation [39]. This exemplifies the fact that nephrologists
can, and need to, advocate early planning for vascular
access placement. At stage IV CKD, the patient who is not
anticipated to receive a transplant within 6 months or
undergo PD should be referred to an experienced vascular
access surgeon, locally or regionally, to be examined for
permanent access. Davidson et al. introduced a mantra
which is especially applicable to the pediatric HD popula-
tion: “The issue is not who places the access but who does
it right, every time, to everyone, and everywhere” [40].
With a potential barrier being lack of surgical expertise, it is
important for the nephrology practitioner to seek an
experienced vascular access surgeon, potentially outside
one’s own institution, to provide optimal patient care.
Choice of center should be outcome and patient driven.
Keeping in mind that an AVF can take up to 6 months to
mature, early placement should be planned. Furthermore, the
patient and family should be educated regarding protection
of the non-dominant arm: avoiding venipunctures, blood
pressure measurements, etc. In addition, it is important that
the placement of peripherally inserted central catheters
(PICCs) be avoided. Education regarding cannulation, with
the use of a child life specialist, recreational therapist, or
peer-to-peer observation/interaction, can be valuable in
cannulation preparedness. In essence, a catheter avoidance
approach should be undertaken whenever possible.
When one is considering which type of access to place,
particular importance should be placed on the preoperative
surgical management. A good physical examination in-
cludes evaluation of the quality of arterial pulse, to assess
for arterial occlusion or impairment of arterial flow. This is
particularly true in those patients with a history of peripheral
arterial lines. Venous elasticity can be assessed by measure-
ment of venous caliber before and after venostasis is
applied, and venous length can be assessed by manual
percussion and palpation of the vessel [19]. Elevation of the
limb above the head can be used for the assessment of
venous drainage. By taking a thorough history and
conducting a physical examination, one completes the
initial office-based evaluation for AVF creation.
Owing to the small vessels of pediatric patients,
radiographic tools can be utilized to assess vascular
adequacy better. For example, Gradman et al. reported
using bedside duplex ultrasound conducted by the surgeon
in person to assess vessel caliber [13]. Others have utilized
venography to evaluate vessel length, caliber, and distal and
central patency [13, 23].
Intraoperative adjuncts previously reported include
loupes, microsutures, and the operating microscope. In fact,
some have advocated the use of microsurgical techniques to
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hemodialysis population [14]. Additional intraoperative
adjuncts reported include the use of an inflatable tourniquet
to provide maximal exsanguination of the vessel, providing
a controlled hemostasis to decrease arterial spasm and
microvascular bleeding [14].
If an AVF fails to show signs of maturation within 4–
6 weeks of placement, or it develops secondary failure, an
evaluation should be conducted. Some have advocated the
use of routine ultrasound post-operatively to assure patency
and the possibility of deep vein location. In the case of deep
location of the vein, the AVF may be patent but inaccessible
[41]. As such, surgical transposition to superficialize the
vein is most often required. Alternatively, if a stenosis is
present, it can be either dilated or surgically revised. If the
AVF was placed within 4 weeks, surgery should be
considered, as angioplasty may put the anastomosis at risk
of rupture. However, if the AVF has been in place for more
than 4 weeks, an experienced interventional radiologist
should be consulted. Angiography is often performed, and
stenosis, if found, may be treated with angioplasty. Again, it
is important for the practitioner to be responsive to all
access failures and to intervene early so as to optimize the
long-term success of the AVF.
Ongoing monitoring
Once an AVF has been created and successfully used, it is
imperative that ongoing maintenance be performed to
allow a long life of use. Overall, proactive monitoring of
vascular access can decrease frequency of thrombosis and
hospitalization. Although monitoring the CVC mostly
involves troubleshooting as problems arise, surveillance
of AVFs and AVGs is quite plausible. Many times, nursing
personnel are the first to detect problems, as exemplified
by difficulty in cannulation, poor blood flows, pain, or
prolonged bleeding from needle sites. Many techniques for
ongoing monitoring have been suggested and include static
venous pressure monitoring, dynamic venous pressure
monitoring, and ultrasound dilution techniques. Chand et
al. reported that dynamic venous pressure monitoring does
not adequately predict access failure in pediatric hemodi-
alysis patients when the patients are used as their own
historic controls [42]. Although not a randomized con-
trolled trial, it was the only study evaluating venous
pressure monitoring in a pediatric patient population to
date. Goldstein et al. described the use of an ultrasound
dilution technique on a regular basis in pediatric HD
patients in order to improve the life of the access [43]. Use
of the ultrasound dilution method to monitor the access
resulted in a 50% reduction in the number of patients
hospitalized, and a significant reduction of costs associated
with these hospitalizations. Use of the ultrasound dilution
method can decrease morbidity and be a useful adjunct in
vascular access management in pediatric patients. This is
further supported by the NKF/K-DOQI guidelines for
pediatric vascular access [44]. Many times, the ongoing
surveillance can be made into a protocol to allow early
intervention as warranted. Although there are minor
differences between AVF and AVG regarding anatomy
and vascular compliance, at this point, no separate
pediatric monitoring or intervention guidelines regarding
stenosis/thrombosis exist.
Based on review of the current literature, the authors
would propose the following as tools for ongoing monitor-
ing of AVFs and AVGs:
1. Inspection: the access should be assessed weekly via
inspection, palpation, and auscultation by the nursing
staff, with specific attention to arm swelling, prolonged
bleeding after needle removal, or change in thrill or bruit.
The nephrologist should also inspect the access at each
physical examination. Any difficulties in needle cannu-
lationordecreasesin blood flow duetoelevatednegative
arterial pump pressures should be noted, as well.
2. Surveillance: decreases in Kt/Vor urea reduction ratios
should be noted. Determination of access recirculation
should be documented on a monthly basis, as well. An
adjunct should be used to determine blood flow
through the vascular access. If the equipment is
available, ultrasound dilution measurements should be
performed by a consistent person each month. If such
equipment is not available, a Doppler ultrasound can be
performed each month.
3. Referral: referral for fistulogram with possible angio-
plasty should be made if there is (1) inadequate blood
flow, thereby compromising adequacy, (2) elevated
access recirculation (>20% after correction of the
needle position), (3) corrected access flow less than
650 ml/min per 1.73m
2 body surface area by ultrasound
dilution techniques, (4) consistent abnormality on
Doppler ultrasound, or (5) pseudoaneurysm has formed
(note: rotation of puncture sites can help minimize risk
of pseudoaneurysm formation).
Monthly review of vascular access should be conducted
by a multidisciplinary team, ideally involving the nephrol-
ogist, nursing staff, and the vascular access surgeon.
Summary
Vascular access in the pediatric HD patient is a challenging,
but necessary, undertaking for the practitioner. It requires
proper advance planning to assure that the best permanent
access is placed, seamless communication involving a
1126 Pediatr Nephrol (2009) 24:1121–1128multidisciplinary team of nephrologists, nurses, surgeons,
and interventional radiologists, and ongoing monitoring to
ensure its long life span. It is imperative that the practitioner
have a long-term vision to decrease morbidity in this
unique patient population. We recommend an approach to
minimize/avoid the prolonged use of CVCs due to risks of
infection and the need for vessel preservation. We encour-
age the practitioner to use good clinical judgment when
choosing the appropriate vascular access in each patient.
Questions
(Answers appear after the reference list)
1. Which of the following members should not be
involved as part of a multidisciplinary team approach
to successful AVF creation?
a. Experienced hemodialysis nurses
b. Interventional radiologists
c. Pediatric nephrologists
d. Recreational therapists/child life specialists
e. Vascular access surgeons
f. None of the above (all should be involved)
2. All of the following are potential complications of
CVC use in pediatric hemodialysis patients except:
a. Infection
b. Malfunction
c. Steal phenomenon
d. Thrombosis
3. Of the following, which is the best method for ongoing
surveillance of AVF?
a. Dynamic venous pressure monitoring
b. Static venous pressure monitoring
c. Troubleshooting once a problem arises
d. Ultrasound dilution
4. A 10-year-old boy has a left radiocephalic AVF created,
and, 2 weeks after placement, there is no longer a bruit
or palpable thrill. Bedside Doppler ultrasound does not
show flow through the access. What would be the next
step in the management of this patient’s condition?
a. Conduct an evaluation for hypercoagulable state
b. Infusetissueplasminogenactivatorthroughthefistula
c. Refer the patient to interventional radiology
d. Refer the patient to the vascular access surgeon
5. All of the following are factors to be considered in site
selection of AVF creation except:
a. Extremity contractures
b. Prior metacarpal fracture
c. Pulse quality
d. Vessel size
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